Pharmaceutical PV DIV - FSB
Ended Awarded Last action
- Contract number
- SPE2DU26FENSK
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $2,265
Award facts
- Contract value 100% obligated
- $2,264.50 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $2,264.50 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois. This delivery order, issued on December 10, 2025, represents one of multiple orders issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) established through the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. The broader PPV-G GEN V acquisition strategy, valued at $30.3 billion, positions DMS Pharmaceutical Group as a regional prime vendor contractor responsible for supplying comprehensive pharmaceutical products including branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables to support Department of Defense military healthcare facilities worldwide. No set-aside designation was used for this particular delivery order, demonstrating the company's competitive capability in unrestricted federal procurement.
DMS Pharmaceutical Group's prime vendor contract (SPE2DR), awarded on November 13, 2025, carries a ceiling value of $499,999,999 with an ultimate completion date of December 31, 2036, structured as a 30-month base period with three 30-month option periods. The company's established performance distributing critical medications such as oncology treatments, immunosuppressants, emergency pharmaceuticals, and routine drugs has demonstrated its capability to fulfill the specialized pharmaceutical requirements of the federal military medical system. As the prime contractor for this delivery order, DMS Pharmaceutical Group operates with no identified subcontractors, maintaining direct responsibility for fulfilling all pharmaceutical supply requirements issued by the DLA's Medical Supply Chain division.
Quick answers
Who was awarded contract SPE2DU26FENSK?
SPE2DU26FENSK was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 10, 2025.
How much is contract SPE2DU26FENSK worth?
The government has obligated $2,265 on SPE2DU26FENSK.
Is contract SPE2DU26FENSK an order under another contract?
Yes. SPE2DU26FENSK is a delivery order under SPE2DU25D9420, an indefinite delivery contract.
Was contract SPE2DU26FENSK competed?
The extent of competition for SPE2DU26FENSK was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award